Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings in Brief: Imatron

This article was originally published in The Gray Sheet

Executive Summary

Imatron: Completes $16 mil. private placement, funds from which will go to its HeartScan Imaging Inc. subsidiary, which provides coronary artery disease risk assessment using Imatron's Ultrafast CT scanner. Proceeds will allow HeartScan to "implement its plan for accelerating the opening of new centers" and "will allow us to establish HeartScan as a separate business which we expect will provide Imatron with a very strong continuing source of orders for our Ultrafast CT scanners as well as continued significant participation in HeartScan's service revenue stream," Imatron says. Investors in the placement include: SC Fundamental Value Fund, Cramer Rosenthal McGlynn, and Gruber & McBaine...

You may also be interested in...

Former MiMedX Execs Convicted On Securities Fraud Charges

The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.

First-Of-Its-Kind Prostate Cancer Imaging Agent Approved By FDA

Gallium has been approved as a diagnostic agent by the US agency to help early detection of prostate cancer spread in patients who qualify for treatment with surgery or radiation therapy.

GAO/NAS Report On AI In Health Care Critical Of FDA Slowness On SaMD Rulemaking

A joint report by the US Government Accountability Office and the National Academy of Sciences slams the FDA for dawdling on final software as a medical device rules.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts